EPISODE
Eric Goldman, Nima Jalali, Jon McNeill, Karri Saarinen, Dimi Kellari, Mikey Shulman
00:01:00 Eric Goldman, Associate Dean for Research and Professor of Law at Santa Clara University School of Law, specializes in Internet Law, Intellectual Property, and Advertising & Marketing Law. He discusses the recent California state court case where a jury awarded $6 million in damages to a plaintiff who alleged that social media platforms contributed to her mental health issues. Goldman highlights the broader implications of this verdict, noting that it could set a precedent for numerous similar lawsuits pending across the country, potentially leading to significant financial liabilities for social media companies and prompting changes in platform design and regulation.
00:02:00 Nima Jalali, a former professional snowboarder from Los Angeles, is the founder and CEO of Salt & Stone, a natural skincare brand established in 2017. In the conversation, he discusses his transition from snowboarding to entrepreneurship, emphasizing the importance of creating high-performing, design-led products that resonate with consumers. Jalali highlights the brand's rapid growth, its focus on quality and authenticity, and the significance of building a lasting legacy through relentless dedication and strategic partnerships.
00:03:00 Jon McNeill, an American businessman and entrepreneur, has held prominent roles including President of Global Sales and Service at Tesla and Chief Operating Officer at Lyft. In the conversation, he discusses the operational framework he developed at Tesla, emphasizing principles such as questioning every requirement, simplifying processes, accelerating workflows, and automating last. He illustrates these concepts with examples, like reducing Tesla's online purchase process from 64 to 20 clicks by eliminating non-essential steps, and highlights the importance of maintaining focus and agility within organizations to drive innovation and efficiency.
00:04:00
00:05:00 Dimi Kellari, co-founder and CEO of Neon Bio, discusses how his company genetically engineers chickens to produce medicines within their eggs, aiming to reduce drug manufacturing costs and enhance accessibility. With a background in aerospace engineering, Kellari transitioned to biotech to address challenges in drug pricing and supply chains. He highlights a recent commercial deal to bring up to three biosimilar drugs to market, emphasizing the scalability of their approach, where a few thousand chickens can produce the global supply of a drug like Humira.
00:06:00